Telavancin
Also known as: TD-6424, Telavancin dihydrochloride, televancin, TLV, Vancocin, Vibativ
Source Telavancin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Telavancin is a semisynthetic lipoglycopeptide derived from vancomycin, administered intravenously for treatment of serious Gram‑positive infections such as MRSA‑related skin and soft‑tissue infections and hospital‑acquired bacterial pneumonia.
Mechanism of Action
Binds D-Ala-D-Ala terminus of cell wall precursors inhibiting peptidoglycan synthesis and disrupts bacterial cell membrane potential leading to depolarization.
Routes of Administration
Goals & Uses
- Treatment of ventilator-associated bacterial pneumonia (VABP)Antibacterial / Infection TreatmentHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Treatment of bacteremia due to Gram-positive organismsAntibacterial / Infection TreatmentModerate
- Treat hospital‑acquired bacterial pneumoniaInfectionHigh
- Treatment of complicated skin and skin structure infections (cSSSI)Antibacterial / Infection TreatmentHigh
- Target methicillin‑resistant Staphylococcus aureus (MRSA)AntimicrobialHigh
- Treat complicated skin and skin structure infectionsInfectionHigh
- Treatment of hospital-acquired bacterial pneumonia (HABP)Antibacterial / Infection TreatmentHigh
Contraindications
- Use with QTc-prolonging agents in patients with known QT prolongationCardiacModerate
- Severe renal impairment (CrCl <30 mL/min) without dose adjustmentRenalModerate
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to telavancin or any componentAllergyHigh
- Severe renal impairment (CrCl <10 mL/min)RenalHigh
- Hypersensitivity to telavancin, vancomycin, or other glycopeptidesAllergyHigh
Adverse Effects
- QT interval prolongationCardiacRare
- ThrombocytopeniaHematologicUncommonLow platelet count
- Interference with coagulation tests (PT, INR, aPTT)LaboratoryCommon
- QTc prolongationCardiacUncommon
- Taste disturbance (dysgeusia)SensoryCommon
- Foamy urineRenal / UrinaryCommon
- Infusion‑related reactionsGeneralCommon
- Nausea and vomitingGastrointestinalCommon
- Nephrotoxicity (renal impairment)RenalCommon
- NephrotoxicityRenalCommon
- Infusion-related reactions (Red Man Syndrome)Infusion ReactionCommon
Drug Interactions
- AminoglycosidesHigh
- Nephrotoxic agents (aminoglycosides, NSAIDs, amphotericin B)High
- WarfarinLow
- Other QT‑prolonging drugs (e.g., macrolides, fluoroquinolones)Moderate
- QTc-prolonging drugs (e.g., haloperidol, amiodarone, fluoroquinolones)Moderate
- Unfractionated HeparinLow
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patients (<18 years)AgeAbsolute
- Pediatric patientsAgeRelative
- Women of childbearing potential without contraceptionReproductiveRelative
- Patients with known QT prolongation or congenital long QT syndromeCardiacRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaEMA approval 2010
- United StatesApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaApproved 2009
- United KingdomApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaApproved under same indications as EU
FDA approved in 2009 (Vancocin) for cSSSI and HABP/VABP; EMA approval 2010; not approved for pediatric patients under 18.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Telavancin?
Telavancin is a semisynthetic lipoglycopeptide derived from vancomycin, administered intravenously for treatment of serious Gram‑positive infections such as MRSA‑related skin and soft‑tissue infections and hospital‑acquired bacterial pneumonia.
What is Telavancin used for?
Telavancin is educationally associated with: Treatment of ventilator-associated bacterial pneumonia (VABP), Treatment of MRSA infections, Treatment of bacteremia due to Gram-positive organisms, Treat hospital‑acquired bacterial pneumonia, Treatment of complicated skin and skin structure infections (cSSSI), Target methicillin‑resistant Staphylococcus aureus (MRSA), Treat complicated skin and skin structure infections, Treatment of hospital-acquired bacterial pneumonia (HABP). Educational only — not medical advice.
How is Telavancin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Telavancin?
Reported adverse effects include: QT interval prolongation, Thrombocytopenia, Interference with coagulation tests (PT, INR, aPTT), QTc prolongation, Taste disturbance (dysgeusia), Foamy urine, Infusion‑related reactions, Nausea and vomiting, Nephrotoxicity (renal impairment), Nephrotoxicity, Infusion-related reactions (Red Man Syndrome). This list is not exhaustive — consult a qualified clinician.
Who should avoid Telavancin?
Recorded contraindications: Use with QTc-prolonging agents in patients with known QT prolongation, Severe renal impairment (CrCl <30 mL/min) without dose adjustment, Pregnancy, Hypersensitivity to telavancin or any component, Severe renal impairment (CrCl <10 mL/min), Hypersensitivity to telavancin, vancomycin, or other glycopeptides. Consult a qualified clinician before use.